Celcuity (CELC) Net Income towards Common Stockholders (2016 - 2025)
Celcuity (CELC) posted Net Income towards Common Stockholders of -$51.0 million for Q4 2025, down 16.37% on a QoQ basis from -$43.8 million in Q3 2025, and down 39.07% year-over-year from -$83.7 million in Q4 2024.
Celcuity (CELC) Net Income towards Common Stockholders (2016 - 2025) Analysis & Trends
Celcuity's Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at -$51.0 million for Q4 2025.
- Quarterly Net Income towards Common Stockholders fell 39.07% year-over-year to -$51.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$177.0 million (down 58.39% YoY) and the FY2025 annual result came in at -$139.9 million, down 24.38% from the prior year.
- Net Income towards Common Stockholders was -$51.0 million for Q4 2025 at Celcuity, down from -$43.8 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$2.8 million in Q1 2021 and bottomed at -$51.0 million in Q4 2025.
- A 5-year average of -$21.1 million and a median of -$16.5 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders sank 1104.06% — and 2022, when it climbed 29.02%.
- Celcuity's Net Income towards Common Stockholders stood at -$6.8 million in 2021, then slumped by 71.49% to -$11.6 million in 2022, then plunged by 62.75% to -$18.8 million in 2023, then slumped by 94.46% to -$36.7 million in 2024, then slumped by 39.07% to -$51.0 million in 2025.
- Business Quant data shows CELC's Net Income towards Common Stockholders at -$51.0 million in Q4 2025, -$43.8 million in Q3 2025, and -$45.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Celcuity | 3.89 Bn | 3.89 Bn | - | -50.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -50.97 Mn |
| Sep 30, 2025 | -43.80 Mn |
| Jun 30, 2025 | -45.27 Mn |
| Mar 31, 2025 | -37.00 Mn |
| Dec 31, 2024 | -36.65 Mn |
| Sep 30, 2024 | -29.79 Mn |
| Jun 30, 2024 | -23.72 Mn |
| Mar 31, 2024 | -21.61 Mn |
| Dec 31, 2023 | -18.85 Mn |
| Sep 30, 2023 | -18.40 Mn |
| Jun 30, 2023 | -14.59 Mn |
| Mar 31, 2023 | -11.94 Mn |
| Dec 31, 2022 | -11.58 Mn |
| Sep 30, 2022 | -10.89 Mn |
| Jun 30, 2022 | -9.96 Mn |
| Mar 31, 2022 | -7.93 Mn |
| Dec 31, 2021 | -6.75 Mn |
| Sep 30, 2021 | -6.03 Mn |
| Jun 30, 2021 | -14.03 Mn |
| Mar 31, 2021 | -2.79 Mn |